Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
23
03
2023
accepted:
11
07
2023
revised:
23
06
2023
medline:
11
12
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Pharmacogenomic technology is a developing field with enthusiastic interest and broad application potential. Three large, controlled studies have been published exploring the benefit of pharmacogenomically guided antidepressant treatment selection. Though all three studies did not show significant benefit of using this technology, these studies laid the foundation for further research that should address the limitations of this previous research and currently available commercial platforms. Future research needs to include large scale pharmacogenomic trials with GWAS analytics across diverse groups with attention to cost-effectiveness models, particularly for cases of treatment resistance and polypharmacy. The application of results from these large scale pharmacogenomic trials must also include exploring optimal EHR user interface design.
Identifiants
pubmed: 37550439
doi: 10.1038/s41386-023-01667-4
pii: 10.1038/s41386-023-01667-4
pmc: PMC10700565
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
282-284Informations de copyright
© 2023. The Author(s).
Références
Am J Psychiatry. 2015 Aug 1;172(8):751-9
pubmed: 25815420
BMC Psychiatry. 2019 Dec 27;19(1):420
pubmed: 31881956
JAMA. 2022 Jul 12;328(2):151-161
pubmed: 35819423
J Clin Psychiatry. 2015 Oct;76(10):e1320-3
pubmed: 26528658
J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):46-55
pubmed: 34099307
Depress Anxiety. 2020 Sep;37(9):834-841
pubmed: 32383277
Am J Psychiatry. 2018 Mar 1;175(3):251-261
pubmed: 29241359
J Affect Disord. 2019 Mar 1;246:62-68
pubmed: 30578947
Am J Psychiatry. 2018 Sep 1;175(9):873-886
pubmed: 29690793
J Clin Psychopharmacol. 2023 Sep-Oct 01;43(5):428-433
pubmed: 37683232
J Clin Psychiatry. 2019 Oct 31;80(6):
pubmed: 31721487
J Psychiatr Res. 2019 Apr;111:59-67
pubmed: 30677646